Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

Makary announced in May that he intended for the FDA to fully integrate generative AI into its work by the end of June; that ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

Angelini’s investments will be made through its Angelini Ventures arm. EIB and Angelini plan to support between seven and 10 ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Researchers said they have uncovered a novel sign of chronic stress and its damaging effects on the body by using an ...

Though artificial intelligence has long made a name for itself in imaging—with hundreds of programs able to automate separate ...

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. | ...

Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...